Don’t Forget to Link Your ORCID iD to Your eRA Commons Profile
Graduate students to senior scientists are encouraged to register for an ORCID account (https://orcid.org/register) and
link it to their eRA Commons personal profile
(https://era.nih.gov/erahelp/ppf/default.htm#PPF_Help/8_2_orcid.htm%3FTocPath%3D_____13). Starting October 1, 2019,
ORCID identifiers will be required for individuals supported by institutional research training, career development, and
other research education awards. xTrain appointments will not be accepted for agency review if potential appointees do
not have an ORCID iD linked to their eRA personal profile. ORCID iDs will also be required for PD/PIs on individual
fellowship and career development applications submitted for due dates on or after January 25, 2020.
“Privacy and Health Research in a Data-Driven World” – Live Webcast – Thursday, September 19, 2019 from
8:15AM to 4:15PM EDT.
Sessions will include:
• Is Privacy a Casualty of Advancing Research?
• Approaches to Protecting Privacy and Confidentiality
• Protecting Privacy and Confidentiality: A Shared Responsibility
For additional information go to: https://www.hhs.gov/ohrp/education-and-outreach/exploratory-workshop/2019-workshop/index.html
The Office of Technology Development will offer the Innovation to Impact Series Session 2 “Aligning Your
Research With Industry.” Learn how to gather useful insights from the market; Common customer discovery mistakes; and
Funding to support market discovery. Meredith Wilkerson, Licensing Officer -Life Sciences and Andrew Pollock, Interim Exec.
Director of OTD will be presenting.
This session will occur on September 25th from Noon- 1:00 pm in Biomedical Research Center Building, Room 103. Lunch
will be provided. Please RSVP to firstname.lastname@example.org by September 23rd. Space is limited to the first 15 attendees.
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Small Business
Innovation Research (SBIR) and Small Business Technology Transfer (STTR) experts are coming to Oklahoma
City to conduct an SBIR Outreach Event.
Wednesday, September 25th from 9:00 am to 4:00 pm at the OUHSC PHF Conference Center.
See the attached document for additional information.
https://research.ouhsc.edu/Portals/1329/Assets/Documents/NIH Contract SBIR Topics.docx?ver=2019-08-18-153311-077
Office of Technology Development presents a third opportunity to engage with industry
(for more information go to http://www.ou.edu/otd/ICO, or email email@example.com for specific submission details):
Almirall is looking to sponsor academic research for target identification, validation, and/or to advance pre-clinical therapeutic
opportunities into clinical settings for “novel targets, pathways, or therapeutic candidates relating to chronic immune-inflammatory
disease” (expiration 9/30/19). Funding up to $250K per project to be awarded by Almirall in November 2019.
Harold Hamm Diabetes Center (HHDC) Research Symposium CALL FOR ABSTRACTS
The abstract submission deadline for the HHDC 2019 Research Symposium is Friday, October 4th. Abstracts must be received
by 5 p.m. HHDC 2019 Research Symposium will be held on Friday, November 15, 2019 at the Samis Education Center in Children’s
Hospital in Oklahoma City. The Symposium will consist of selected oral presentations, a poster session, and Symposia talks by
P. Darrell Neufer, PhD, Professor, East Carolina University, Matthew Rodeheffer PhD, Associate Professor, Yale University and
Scott Summers, PhD, Professor and Chair, The University of Utah. For abstract submission guidelines and to RSVP for this free
event, please go to: https://hammdiabetescenter.org/Research/Symposium Please contact Katie-Hoefling@ouhsc.edu with any
questions for this event.
Save the Date – ORA Noon Conference
Navigating the ORA Proposal Submission Process
Speaker(s): Caitlin Novotny, Sponsored Programs Administrator, Office of Research Administration
Offered: September 25, 2019 LIB-299 12-1pm
Overview: This session will cover the basics of proposal preparation and map out the process of submission through the
Office of Research Administration. We will discuss what your Sponsored Programs Administrator looks for during the pre-award
review, such as budget considerations, eligibility, and compliance with applicable rules and policies. We will also cover topics
related to proposal submission, such as grant routing forms and the systems used to submit federal grants. The overall goal of
this presentation is to provide a basic understanding of and advice on proposal preparation and submission
Notice of Special Interest to Encourage Eligible NIH BRAIN Initiative Awardees to Apply for PA-18-906 Research Supplements
to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) (NOT-MH-19-038)
Notice of Pre-Application Webinar for RFA-AT-20-001, Preclinical Screening for Natural Product Drug Interactions (R21) and
RFA-AT-20-002, Center of Excellence for Natural Product Drug interaction Research (U54) (NOT-AT-19-034)
Pre-Application Webinar for RFA-CA-19-033 " Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors
(U01 Clinical Trial Required)" (NOT-CA-19-068)
The National Institutes of Health (NIH) Sexual & Gender Minority Research Office (SGMRO) Announces Mid-Atlantic Regional
Workshop on Sexual and Gender Minority (SGM)-Related Health Research (NOT-OD-19-142)
Request for Information (RFI): Soliciting Additional Input to the All of Us Research Program 2019 Tribal Consultation (NOT-PM-19-004)
Notice of Increased Budget Limits and NINDS Participation in PAS-19-316 "Advancing Research on Alzheimer's Disease (AD)
and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)" (NOT-AG-19-040)
Notice of Change to Information relevant to Specific Institutes/Centers in PAR-19-274, "Dissemination and Implementation
Research in Health (R01 Clinical Trial Optional)" (NOT-AR-19-040)
Notice of Change to Information relevant to Specific Institutes/Centers in PAR-19-275, "Dissemination and Implementation
Research in Health (R21 Clinical Trial Optional)" (NOT-AR-19-041)
Notice of Correction to Award Budget for RFA HD-20-006 "US Children with Perinatal HIV who were Born Internationally
(R01 Clinical Trial Optional)" (NOT-HD-19-025)
NHLBI Announces Participation in PA-18-932 "Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations
(R01 Clinical Trial Optional)" (NOT-HL-19-719)
Notice to Extend, PA-18-400 "Research on Autism Spectrum Disorders (R21-Clinical Trial Optional)"
Notice to Extend, PA-18-401 "Research on Autism Spectrum Disorders (R01-Clinical Trial Optional)"
Notice to Extend, PA-18-399 "Research on Autism Spectrum Disorders (R03-Clinical Trial Optional)"
Notice to Extend, PAR-18-479, "Detecting and Preventing Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the
Juvenile Justice System (R01 Clinical Trial Required)" (NOT-MH-19-049)
Notice to Extend, PAR-18-228, "Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact
with the Juvenile Justice System (R34 Clinical Trial Required)" (NOT-MH-19-050)
Notice of Intent to Publish a Funding Opportunity Announcement for the Pediatric HIV AIDS Cohort Study Program Project Grant
Applications (P01 Clinical Trial Not Allowed) (NOT-HD-19-024)
Notice of Special Interest: High-Priority Research Topics for PA-19-053 and PA-19-056 (NOT-AG-19-037)
Notice of Special Interest (NOSI) of NIDCD and NEI in Supporting Research on Usher Syndrome
Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research
Expertise in Diabetes, Endocrinology and Metabolic Diseases (NOT-DK-19-015)
Notice of Special Interest: Research to Improve Pre-Pregnancy Care and Enhance Healthy Birth Intervals
Notice of Special Interest: Mechanisms Underlying the Contribution of Sleep Disturbances to Pain
Please Note: When only one application is allowed per Institution according to the sponsor
instructions, a one-page letter of intent summarizing the proposed project should be submitted
to the Vice President for Research at least one month prior to the application deadline (unless
otherwise noted). The letters of intent will be reviewed and a single application will be chosen
for submission from the University.
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)
(PAR-19-357) – Deadline January 8, 2020 and January 8, 2021
Planning Grant for Global Infectious Disease Research Training Program (D71 No Clinical Trials Allowed)
(PAR-19-362) – Deadline November 12, 2019 and October 28, 2020
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
(PAR-19-363) – Deadline October 5, 2019
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)
(PAR-19-364) – Deadline January 8, 2020 and January 8, 2021
Revision Applications for Mechanisms of Drug Resistance (R01 Clinical Trials Not Allowed) (RFA-CA-19-049)
Deadline October 24, 2019 and June 24, 2020
Revision Applications for Mechanisms of Drug Resistance (U01 Clinical Trials Not Allowed)
(RFA-CA-19-050) – Deadline October 24, 2019 and June 24, 2020
Revision Applications for Mechanisms of Drug Resistance (U54 Clinical Trials Not Allowed)
(RFA-CA-19-051) – Deadline October 24, 2019 and June 24, 2020
Revision Applications for Mechanisms of Drug Resistance (P01 Clinical Trials Not Allowed)
(RFA-CA-19-052) – Deadline October 24, 2019 and June 24, 2020
Revision Applications for Mechanisms of Drug Resistance (P50 Clinical Trials Not Allowed)
(RFA-CA-19-053) - Deadline October 24, 2019 and June 24, 2020
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
(RFA-DA-20-024) – Deadline November 15, 2019
Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Clinical Research Centers
(U01 Clinical Trial Optional) (RFA-DK-19-015) – Deadline November 7, 2019
Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Scientific and Data Coordinating Center
(U24 Clinical Trial Optional) (RFA-DK-19-016) – Deadline November 7, 2019
Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research
(R21 Clinical Trial Not Allowed) (RFA-HD-20-020) – Deadline November 1, 2019
Trans-Agency Blood-Brain Interface Program (R61/R33 - Clinical Trials Not Allowed) (RFA-HL-20-021)
Deadline December 2, 2019 and October 19, 2020
Mechanistic Basis of TDP-43-dependent Pathobiology in Common Dementias (R01 Clinical Trial not Allowed)
(RFA-NS-20-005) – Deadline November 15, 2019
Peripheral Pathology in the Lewy Body Dementias (R01 Clinical Trial Not Allowed)
(RFA-NS-20-014) - Deadline December 3, 2019